SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 02/27/2026 at 13:03, 23 days 7 hours ago

Communiqué de presse : Dupixent de Sanofi et Regeneron recommandé pour approbation dans l'UE dans le traitement de l'urticaire chronique spontanée chez les jeunes enfants dont les symptômes persistent malgré un traitement
Le Dupixent de Sanofi et Regeneron est recommandé pour l'approbation dans l'UE pour traiter l'urticaire chronique spontanée chez les jeunes enfants. Décision finale à venir

Sanofi Dupixent Enfants Regeneron Urticaire
PRESS RELEASE

published on 02/27/2026 at 13:03, 23 days 7 hours ago

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment. Positive CHMP opinion based on clinical studies

Sanofi Dupixent EU Approval CSU Regeneron
BRIEF

published on 02/24/2026 at 15:35, 26 days 5 hours ago

Sanofi and Regeneron's Dupixent Gains FDA Approval for AFRS Treatment

FDA Approval Type 2 Inflammation Dupixent Approval Allergic Fungal Rhinosinusitis Sanofi And Regeneron
BRIEF

published on 02/24/2026 at 15:35, 26 days 5 hours ago

Dupixent, développé par Sanofi et Regeneron, obtient l'approbation de la FDA pour le traitement de la fibrillation auriculaire.

Approbation De La FDA Inflammation De Type 2 Rhinosinusite Fongique Allergique Approbation Dupixent Sanofi Et Regeneron
PRESS RELEASE

published on 02/24/2026 at 15:30, 26 days 5 hours ago

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease

Sanofi Phase 3 Study Dupixent Regeneron Allergic Fungal Rhinosinusitis
PRESS RELEASE

published on 02/24/2026 at 15:30, 26 days 5 hours ago

Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique
Dupixent de Sanofi et Regeneron approuvé par la FDA aux États-Unis pour traiter la rhinosinusite fongique allergique, offrant un soulagement aux patients de tous âges

Traitement Sanofi Dupixent Regeneron Rhinosinusite Fongique Allergique
BRIEF

published on 02/17/2026 at 19:05, 1 month 5 days ago

Sanofi publishes its 2025 Universal Registration Document

Sustainability Financial Report Sanofi Registration Document DRY
BRIEF

published on 02/17/2026 at 19:05, 1 month 5 days ago

Sanofi publie son Document d'Enregistrement Universel 2025

Rapport Financier SEC Durabilité Sanofi Document D'enregistrement
PRESS RELEASE

published on 02/17/2026 at 19:00, 1 month 5 days ago

Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain
Dépôt du Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel et du « Form 20-F » américain par Sanofi. Consultation en ligne disponible

Rapport Financier Annuel Form 20-F Document D’enregistrement Universel Sanofi Consultation En Ligne
BRIEF

published on 02/17/2026 at 12:05, 1 month 5 days ago

Sanofi et Teva annoncent des résultats positifs de phase 2b pour Duvakitug dans les MICI

Maladie De Crohn Rectocolite Hémorragique Étude De Phase 2b Duvakitug Collaboration Sanofi-Teva

Published on 03/20/2026 at 23:00, 1 day 21 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 1 day 23 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 1 day 23 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 7 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 8 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/22/2026 at 18:22, 2 hours 37 minutes ago

Test news - please ignore EN
Published on 03/22/2026 at 12:23, 8 hours 36 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 22 hours ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 23 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 23 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion

View all EQS

Published on 03/20/2026 at 19:00, 2 days 1 hour ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 1 hour ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 2 hours ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 2 hours ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Published on 03/20/2026 at 17:45, 2 days 3 hours ago

Cie du Bois Sauvage : Jaarverslag 2025

View all LES ECHOS COMFI WIRE

News